Ignite Creation Date:
2024-05-06 @ 7:29 AM
Last Modification Date:
2024-10-26 @ 11:49 AM
Study NCT ID:
NCT02542293
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-29
First Post:
2015-08-26
Brief Title:
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer NSCLC NEPTUNE
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-11-03
Start Date Type:
ACTUAL
Primary Completion Date:
2020-09-21
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2015-08-26
First Submit QC Date:
September 3 2015
Study First Post Date:
2015-09-07
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2022-05-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-30
Last Update Post Date:
2024-05-29
Last Update Post Date Type:
ACTUAL